The role of immune checkpoint inhibitor therapy in advanced adrenocortical carcinoma revisited: review of literature
ConclusionICI, mainly pembrolizumab, is a potential therapeutic option, which is safe and associated with prolonged OS benefit, in selected patients with advanced ACC.
Source: Journal of Endocrinological Investigation - Category: Endocrinology Source Type: research
More News: Adrenocortical Carcinoma | Cancer & Oncology | Carcinoma | Endocrinology | Hepatocellular Carcinoma | Immunotherapy | Liver | Liver Cancer | Rare Diseases | Study | Urology & Nephrology